Zynerba Pharmaceuticals
Manufacturing · Pennsylvania, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
80 Lancaster Ave Ste 300, Devon, Pennsyl...Phone Number
(484) 581-7505Website
www.zynerba.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Zynerba Pharmaceuticals
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.Explore more
Zynerba Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Zynerba Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Zynerba Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Zynerba Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Zynerba Pharmaceuticals recently announced quarterly report
Website visits: Recent activity has been detected on your website
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Zynerba Pharmaceuticals has new funding data
Product Launch: Get notified when Zynerba Pharmaceuticals launches new products
Check out if Zynerba Pharmaceuticals is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Zynerba Pharmaceuticals
Click to see if Zynerba Pharmaceuticals had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Zynerba Pharmaceuticals as Masked Content
Find 2 more new buyers
Compare Similar Companies to Zynerba Pharmaceuticals
Compare insights from companies similar to Zynerba Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Zynerba Pharmaceuticals is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Zynerba Pharmaceuticals is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Zynerba Pharmaceuticals.
Zynerba Pharmaceuticals financials insights
Gather financial insights about Zynerba Pharmaceuticals, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2014
Unspecified
$13M
2015
Stock Offering
$48.3M
2017
Stock Offering
$58M
2018
Stock Offering
$29.9M
Zynerba Pharmaceuticals Tech Stack
A closer look at the technologies used by Zynerba Pharmaceuticals
Most Recent Scoops
Mergers & Acquisitions (M&A)
Left Company
Executive Move
Zynerba Pharmaceuticals has announced that Taylor Ocasio, Deputy General Counsel, has left the organization to join TELA Bio as General Counsel.
Left Company
Executive Move
Left Company
Executive Move
New Hire
Executive Move
Zynerba Pharmaceuticals News & Media
Insider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals Inc
On September 13, 2023, President Terri Sebree of Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) sold 12,401 shares of the company's stock.SHAREHOLDER ALERT: Rigrodsky Law, P.A. Is Investigating Zynerba Pharmaceuticals, Inc. Buyout
Wilmington, Delaware--(Newsfile Corp. - August 15, 2023) - Rigrodsky Law, P.A. is investigating Zynerba Pharmaceuticals, Inc. ("Zynerba") (NASDAQ: ZYNE) regarding possible breaches of fiduciary duties and other violations of law related to Zynerba's agreement to be acquired by Harmony Biosciences Holdings, Inc. Under the terms of the agreement, Zynerba shareholders will receive $1.1059 per share in cash.To learn more about this investigation and your rights, visit:...ZYNE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Zynerba Pharmaceuticals, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) to Harmony Biosciences Holdings, Inc. is fair to Zynerba shareholders. Under the terms of the agreement, Harmony would acquire all outstanding shares of Zynerba for $1.1059 per share in cash, plus one non-tradeable contingent value right per share, representing the right to receive potential additional payments of up to $140 million in the aHARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.
PLYMOUTH MEETING, Pa. and DEVON, Pa., Aug. 14, 2023 /PRNewswire/ -- Harmony Biosciences Holdings, Inc. ("Harmony") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today announced a...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Zynerba Pharmaceuticals
Sign Up For FreeTo access detailed company insights
Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically-produced cannabidiol formulated as a permeation-enhanced gel for tran... Read More
